Click here to get full coverage on Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing - Yahoo Finance

Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing  Yahoo Finance

Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing - Yahoo Finance

Click here to get full coverage on Cybin (CYBN) to Go Public on NEO Exchange on or about Nov 10th - Psychedelic Alpha

Cybin (CYBN) to Go Public on NEO Exchange on or about Nov 10th  Psychedelic Alpha

Cybin (CYBN) to Go Public on NEO Exchange on or about Nov 10th - Psychedelic Alpha

Click here to get full coverage on Chicagoland Youth Basketball Network Opens Registration for April 2-Game and 3-Game Tournaments - Digital Journal

Chicagoland Youth Basketball Network Opens Registration for April 2-Game and 3-Game Tournaments  Digital Journal

Chicagoland Youth Basketball Network Opens Registration for April 2-Game and 3-Game Tournaments - Digital Journal

Click here to get full coverage on Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan

Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer  Stock Titan

Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan

Click here to get full coverage on CYBN Technical Analysis | Trend, Signals & Chart Patterns | CYBIN INC (NYSEARCA:CYBN) - ChartMill

CYBN Technical Analysis | Trend, Signals & Chart Patterns | CYBIN INC (NYSEARCA:CYBN)  ChartMill

CYBN Technical Analysis | Trend, Signals & Chart Patterns | CYBIN INC (NYSEARCA:CYBN) - ChartMill

Click here to get full coverage on Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - MSN

Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High?  MSN

Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - MSN

Click here to get full coverage on New Analyst Forecast: $CYBN Given $55.0 Price Target - Quiver Quantitative

New Analyst Forecast: $CYBN Given $55.0 Price Target  Quiver Quantitative

New Analyst Forecast: $CYBN Given $55.0 Price Target - Quiver Quantitative

Click here to get full coverage on Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker - Sahm

Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker  Sahm

Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker - Sahm

Click here to get full coverage on Cybin alters state to become Helus Pharma for Nasdaq trip - Fierce Pharma

Cybin alters state to become Helus Pharma for Nasdaq trip  Fierce Pharma

Cybin alters state to become Helus Pharma for Nasdaq trip - Fierce Pharma

Click here to get full coverage on Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus

Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq  GuruFocus

Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus

Click here to get full coverage on Millennium entities report 2.397M Cybin shares after >5% stake (CYBN) - Stock Titan

Millennium entities report 2.397M Cybin shares after >5% stake (CYBN)  Stock Titan

Millennium entities report 2.397M Cybin shares after >5% stake (CYBN) - Stock Titan

Click here to get full coverage on Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - Yahoo Finance

Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges  Yahoo Finance

Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - Yahoo Finance

Click here to get full coverage on CYBN Stock Price, Quote & Chart | CYBIN INC (NYSEARCA:CYBN) - ChartMill

CYBN Stock Price, Quote & Chart | CYBIN INC (NYSEARCA:CYBN)  ChartMill

CYBN Stock Price, Quote & Chart | CYBIN INC (NYSEARCA:CYBN) - ChartMill

Click here to get full coverage on Cybin (CYBN) unit Helus shows promising Phase 2 anxiety results for HLP004 - Stock Titan

Cybin (CYBN) unit Helus shows promising Phase 2 anxiety results for HLP004  Stock Titan

Cybin (CYBN) unit Helus shows promising Phase 2 anxiety results for HLP004 - Stock Titan

Click here to get full coverage on New mental health drugmaker steps onto Nasdaq with two late-stage trials - Stock Titan

New mental health drugmaker steps onto Nasdaq with two late-stage trials  Stock Titan

New mental health drugmaker steps onto Nasdaq with two late-stage trials - Stock Titan

Click here to get full coverage on Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy - Yahoo Finance

Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy  Yahoo Finance

Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy - Yahoo Finance

Click here to get full coverage on Cybin (NYSE American: CYBN) to webcast Jefferies London presentation at 12:30 GMT on Nov 17 - Stock Titan

Cybin (NYSE American: CYBN) to webcast Jefferies London presentation at 12:30 GMT on Nov 17  Stock Titan

Cybin (NYSE American: CYBN) to webcast Jefferies London presentation at 12:30 GMT on Nov 17 - Stock Titan

Click here to get full coverage on Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan

Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board  Stock Titan

Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan

Click here to get full coverage on Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News - GuruFocus

Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News  GuruFocus

Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News - GuruFocus

Click here to get full coverage on Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Business Wire

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq  Business Wire

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Business Wire

Click here to get full coverage on Cybin (CYBN) Analyst Rating Update: Canaccord Genuity Lowers PT to $45 | CYBN Stock News - GuruFocus

Cybin (CYBN) Analyst Rating Update: Canaccord Genuity Lowers PT to $45 | CYBN Stock News  GuruFocus

Cybin (CYBN) Analyst Rating Update: Canaccord Genuity Lowers PT to $45 | CYBN Stock News - GuruFocus

Click here to get full coverage on Cybin (CYBN) Initiates $100M At-the-Market Equity Program - GuruFocus

Cybin (CYBN) Initiates $100M At-the-Market Equity Program  GuruFocus

Cybin (CYBN) Initiates $100M At-the-Market Equity Program - GuruFocus

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN - PR Newswire

Click here to get full coverage on Cybin (NYSEAMERICAN:CYBN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat

Cybin (NYSEAMERICAN:CYBN) Stock Price Expected to Rise, Guggenheim Analyst Says  MarketBeat

Cybin (NYSEAMERICAN:CYBN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat

Click here to get full coverage on Cybin (CYBN) to Transfer Listing to Nasdaq in 2026 - GuruFocus

Cybin (CYBN) to Transfer Listing to Nasdaq in 2026  GuruFocus

Cybin (CYBN) to Transfer Listing to Nasdaq in 2026 - GuruFocus

Click here to get full coverage on Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For Momentum (CYBN) - Seeking Alpha

Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For Momentum (CYBN)  Seeking Alpha

Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For Momentum (CYBN) - Seeking Alpha

Click here to get full coverage on Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha

Cybin Stock: Optimism Quickly Fades (NYSE:CYBN)  Seeking Alpha

Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha

Click here to get full coverage on Industry veteran Michael Cola named Cybin (CYBN) chief executive - Stock Titan

Industry veteran Michael Cola named Cybin (CYBN) chief executive  Stock Titan

Industry veteran Michael Cola named Cybin (CYBN) chief executive - Stock Titan

Click here to get full coverage on Cybin (CYBN) Initiates $100 Million At-the-Market Equity Program - GuruFocus

Cybin (CYBN) Initiates $100 Million At-the-Market Equity Program  GuruFocus

Cybin (CYBN) Initiates $100 Million At-the-Market Equity Program - GuruFocus

Click here to get full coverage on Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights  Business Wire

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire

Click here to get full coverage on Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025  Business Wire

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire

Click here to get full coverage on Cybin (CYBN) CEO Steps Down; Shares React - GuruFocus

Cybin (CYBN) CEO Steps Down; Shares React  GuruFocus

Cybin (CYBN) CEO Steps Down; Shares React - GuruFocus

Click here to get full coverage on Cybin Announces $175 Million Registered Direct Offering - Business Wire

Cybin Announces $175 Million Registered Direct Offering  Business Wire

Cybin Announces $175 Million Registered Direct Offering - Business Wire

Click here to get full coverage on Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks

Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January  TipRanks

Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks

Click here to get full coverage on CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm - Business Wire

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm  Business Wire

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Click here to get full coverage on Cybin Initiates At-The-Market Equity Program of up to US$100 Million - Business Wire

Cybin Initiates At-The-Market Equity Program of up to US$100 Million  Business Wire

Cybin Initiates At-The-Market Equity Program of up to US$100 Million - Business Wire

Click here to get full coverage on Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones  Business Wire

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire

Click here to get full coverage on Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference  Business Wire

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire

Click here to get full coverage on Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder  BioSpace

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace

Click here to get full coverage on Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks

Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs  TipRanks

Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks

Click here to get full coverage on Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Hel - GuruFocus

Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Hel  GuruFocus

Cybin (CYBN) to Transfer U.S. Listing to Nasdaq, Rebrands to Hel - GuruFocus

Click here to get full coverage on CYBN|Cybin Inc|Price:8.280| - TradingKey

CYBN|Cybin Inc|Price:8.280|  TradingKey

CYBN|Cybin Inc|Price:8.280| - TradingKey

Click here to get full coverage on Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Business Wire

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results  Business Wire

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Business Wire

Click here to get full coverage on Cybin Announces Senior Leadership Changes - Business Wire

Cybin Announces Senior Leadership Changes  Business Wire

Cybin Announces Senior Leadership Changes - Business Wire

Click here to get full coverage on Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder  Business Wire

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire

Click here to get full coverage on Cybin: Upgrade To Hold - But Don't Get Too Carried Away (NYSE:CYBN) - Seeking Alpha

Cybin: Upgrade To Hold - But Don't Get Too Carried Away (NYSE:CYBN)  Seeking Alpha

Cybin: Upgrade To Hold - But Don't Get Too Carried Away (NYSE:CYBN) - Seeking Alpha

Click here to get full coverage on Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures - Business Wire

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures  Business Wire

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures - Business Wire

Click here to get full coverage on Cybin Inc. Announces CEO Transition as of September 2, 2025 - theglobeandmail.com

Cybin Inc. Announces CEO Transition as of September 2, 2025  theglobeandmail.com

Cybin Inc. Announces CEO Transition as of September 2, 2025 - theglobeandmail.com

Click here to get full coverage on Cybin Inc. Secures $175 Million in Direct Offering to Fund Clinical Programs - TipRanks

Cybin Inc. Secures $175 Million in Direct Offering to Fund Clinical Programs  TipRanks

Cybin Inc. Secures $175 Million in Direct Offering to Fund Clinical Programs - TipRanks

Click here to get full coverage on Cybin Inc. Announces CEO Transition as of September 2, 2025 - TipRanks

Cybin Inc. Announces CEO Transition as of September 2, 2025  TipRanks

Cybin Inc. Announces CEO Transition as of September 2, 2025 - TipRanks

Click here to get full coverage on CYBN Stock Price, News & Analysis - Stock Titan

CYBN Stock Price, News & Analysis  Stock Titan

CYBN Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Business Wire

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics  Business Wire

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Business Wire

Click here to get full coverage on Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics  Business Wire

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire

Click here to get full coverage on Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder  Business Wire

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire

Click here to get full coverage on Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - BioSpace

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase  BioSpace

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - BioSpace

Click here to get full coverage on CYBN Forecast — Price Prediction for 2026. Should I Buy CYBN? - Intellectia AI

CYBN Forecast — Price Prediction for 2026. Should I Buy CYBN?  Intellectia AI

CYBN Forecast — Price Prediction for 2026. Should I Buy CYBN? - Intellectia AI

Click here to get full coverage on Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance

Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025  Yahoo Finance

Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance

Click here to get full coverage on Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003  Business Wire

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire

Click here to get full coverage on Cybin Announces $175 Million Registered Direct Offering - TradingView

Cybin Announces $175 Million Registered Direct Offering  TradingView

Cybin Announces $175 Million Registered Direct Offering - TradingView

Click here to get full coverage on Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner  Yahoo Finance

Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Click here to get full coverage on Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade - Yahoo Finance

Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade  Yahoo Finance

Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade - Yahoo Finance

Click here to get full coverage on Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround - Yahoo Finance

Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround  Yahoo Finance

Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround - Yahoo Finance

Click here to get full coverage on Cybin Inc: Paradigm Changing Ambitions (NYSE:CYBN) - Seeking Alpha

Cybin Inc: Paradigm Changing Ambitions (NYSE:CYBN)  Seeking Alpha

Cybin Inc: Paradigm Changing Ambitions (NYSE:CYBN) - Seeking Alpha

Click here to get full coverage on Cybin: Top Value Psychedelic Stock (NYSE:CYBN) - Seeking Alpha

Cybin: Top Value Psychedelic Stock (NYSE:CYBN)  Seeking Alpha

Cybin: Top Value Psychedelic Stock (NYSE:CYBN) - Seeking Alpha

Click here to get full coverage on Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN) - Seeking Alpha

Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN)  Seeking Alpha

Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN) - Seeking Alpha

Click here to get full coverage on CYBN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI

CYBN Stock: Price, Forecast, Financials & AI Analysis  Intellectia AI

CYBN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI

Click here to get full coverage on Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - Stocktwits

Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish  Stocktwits

CYBN

Price Chart

Key Statistics

Technicals

About CYBN

Latest News

Cybin (NYSEAM:CYBN) Valuation Check After Strategic Move to Nasdaq Global Market Listing - Yahoo Finance

Cybin (CYBN) to Go Public on NEO Exchange on or about Nov 10th - Psychedelic Alpha

Chicagoland Youth Basketball Network Opens Registration for April 2-Game and 3-Game Tournaments - Digital Journal

Advanced Charts

Top Gainers

Top Losers